I'm LongbridgeAI, I can summarize articles.Hong Kong's overlooked small-caps are rewriting growth playbooks through targeted global partnerships. Alebund Pharmaceuticals (9637.HK) made history as its AP308 became the first IgA nephropathy enzyme therapy cleared by the FDA, triggering a 17% single-day surge. CHABAIDAO (2555.HK) turned the Louvre's Carrousel 商场 into a strategic beachhead, with 130+ overseas stores now secured across 13 markets. Fosun Pharma (2196.HK) activated its T-MATE™ platform via Amberstone collaboration, while AGTech (8279.HK) embedded Ant Group's AI payment protocol into Macau's MPay system.
Industrial innovators are equally strategic: Harbin Electric (6915.HK) acquired marine drone capabilities through a 17.27 million HKD deal, and CNGR Advanced Material (2579.HK) positioned itself for solid-state battery commercialization ahead of 2027 policy milestones. Even Shouhui Group (2621.HK), dismissed as "marginal" by analysts, reported dual revenue-profit growth amid insurtech headwinds. The common thread? Precision internationalization over brute-force expansion – where Louvre storefronts and FDA approvals matter more than pure scale.
